Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 272

1.

Bendamustine: rebirth of an old drug.

Cheson BD, Rummel MJ.

J Clin Oncol. 2009 Mar 20;27(9):1492-501. doi: 10.1200/JCO.2008.18.7252. Epub 2009 Feb 17. Review. Erratum in: J Clin Oncol. 2009 Jun 10;27(17):2892.

PMID:
19224851
2.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Dennie TW, Kolesar JM.

Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031. Review.

PMID:
20110042
3.

Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Elefante A, Czuczman MS.

Am J Health Syst Pharm. 2010 May 1;67(9):713-23. doi: 10.2146/ajhp090328. Review.

PMID:
20410545
4.
5.

Bendamustine's emerging role in the management of lymphoid malignancies.

Rummel MJ, Gregory SA.

Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.

PMID:
21530769
6.

Bendamustine in the treatment of chronic lymphocytic leukemia.

Knauf W.

Expert Rev Anticancer Ther. 2009 Feb;9(2):165-74. doi: 10.1586/14737140.9.2.165. Review.

PMID:
19192955
7.

Bendamustine.

Balfour JA, Goa KL.

Drugs. 2001;61(5):631-8; discussion 639-40. Review.

PMID:
11368287
8.

Bendamustine: a new treatment option for chronic lymphocytic leukemia.

Glode AE, Jarkowski A.

Pharmacotherapy. 2009 Nov;29(11):1375-84. doi: 10.1592/phco.29.11.1375. Review.

PMID:
19857152
9.

Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Ujjani C, Cheson BD.

Expert Rev Anticancer Ther. 2010 Sep;10(9):1353-65. doi: 10.1586/era.10.116. Review.

PMID:
20836669
10.

Bendamustine: something old, something new.

Tageja N, Nagi J.

Cancer Chemother Pharmacol. 2010 Aug;66(3):413-23. doi: 10.1007/s00280-010-1317-x. Epub 2010 Apr 8. Review.

PMID:
20376452
11.

Bendamustine: a novel cytotoxic agent for hematologic malignancies.

Blumel S, Goodrich A, Martin C, Dang NH.

Clin J Oncol Nurs. 2008 Oct;12(5):799-806. doi: 10.1188/08.CJON.799-806.

PMID:
18842536
12.

Bendamustine: a new look at an old drug.

Kalaycio M.

Cancer. 2009 Feb 1;115(3):473-9. doi: 10.1002/cncr.24057. Review.

13.

Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.

Plosker GL, Carter NJ.

Drugs. 2008;68(18):2645-60. doi: 10.2165/0003495-200868180-00009. Review.

PMID:
19093705
14.

Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.

Leoni LM.

Semin Hematol. 2011 Apr;48 Suppl 1:S4-11. doi: 10.1053/j.seminhematol.2011.03.002. Review.

PMID:
21530771
15.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD.

J Clin Oncol. 2008 Jan 10;26(2):204-10. doi: 10.1200/JCO.2007.12.5070. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911.

PMID:
18182663
16.

Bendamustine therapy in chronic lymphocytic leukemia.

Masiello D, Tulpule A.

Expert Opin Pharmacother. 2009 Jul;10(10):1687-98. doi: 10.1517/14656560903032698. Review.

PMID:
19527193
17.

Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.

Ujjani C, Cheson B.

Future Oncol. 2011 Jan;7(1):9-14. doi: 10.2217/fon.10.169.

PMID:
21174533
19.

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K; Japanese Bendamustine Lymphoma Study Group..

Cancer Sci. 2010 Sep;101(9):2054-8. doi: 10.1111/j.1349-7006.2010.01633.x.

20.

Supplemental Content

Support Center